» Articles » PMID: 25378964

Optimal Management of Hemophilic Arthropathy and Hematomas

Overview
Journal J Blood Med
Publisher Dove Medical Press
Specialty Hematology
Date 2014 Nov 8
PMID 25378964
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Hemophilia is a hematological disorder characterized by a partial or complete deficiency of clotting factor VIII or IX. Its bleeding complications primarily affect the musculoskeletal system. Hemarthrosis is a major hemophilia-related complication, responsible for a particularly debilitating chronic arthropathy, in the long term. In addition to clotting factor concentrates, usually prescribed by the hematologist, managing acute hemarthrosis and chronic arthropathy requires a close collaboration between the orthopedic surgeon and physiotherapist. This collaboration, comprising a coagulation and musculoskeletal specialist, is key to effectively preventing hemarthrosis, managing acute joint bleeding episodes, assessing joint function, and actively treating chronic arthropathy. This paper reviews, from a practical point of view, the pathophysiology, clinical manifestations, and treatment of hemarthrosis and chronic hemophilia-induced arthropathy for hematologists, orthopedic surgeons, and physiotherapists.

Citing Articles

Evaluating the Cost-Effectiveness of Etranacogene Dezaparvovec Gene Therapy for Hemophilia B Treatment in the USA.

Sarker J, Tice J, Rind D, Walton S Appl Health Econ Health Policy. 2024; .

PMID: 39623116 DOI: 10.1007/s40258-024-00932-x.


Retrospective analysis of hemophilia B in Turkey: identifying main characteristics and treatment options.

Zulfikar B, Koc B, Sahin F, Sasmaz H, Kavakli K, Balkan C Res Pract Thromb Haemost. 2024; 8(7):102588.

PMID: 39582809 PMC: 11585750. DOI: 10.1016/j.rpth.2024.102588.


Superior Prophylactic Effectiveness of a Recombinant FVIIIFc Over Standard Half-Life FVIII in Hemophilia A: A-SURE Study.

Oldenburg J, Hay C, Peyvandi F, Tagliaferri A, Holme P, Alvarez-Roman M Eur J Haematol. 2024; 114(2):248-257.

PMID: 39434416 PMC: 11707817. DOI: 10.1111/ejh.14309.


Teenagers and Adolescents with Hemophilia-Need for a Specific Approach.

Konigs C, Motwani J, Jimenez-Yuste V, Blatny J J Clin Med. 2024; 13(17).

PMID: 39274334 PMC: 11396640. DOI: 10.3390/jcm13175121.


Activated factor X delivered by adeno-associated virus significantly inhibited bleeding and alleviated hemophilic synovitis in hemophilic mice.

Zhang F, Zhou X, Hua B, He X, Li Z, Xiao X Gene Ther. 2024; 31(11-12):544-552.

PMID: 39256611 DOI: 10.1038/s41434-024-00479-5.


References
1.
Rodriguez-Merchan E, Jimenez-Yuste V . The role of selective angiographic embolization of the musculo-skeletal system in haemophilia. Haemophilia. 2009; 15(4):864-8. DOI: 10.1111/j.1365-2516.2009.02015.x. View

2.
Atkins R, Henderson N, Duthie R . Joint contractures in the hemophilias. Clin Orthop Relat Res. 1987; (219):97-106. View

3.
Gilbert M . Prophylaxis: musculoskeletal evaluation. Semin Hematol. 1993; 30(3 Suppl 2):3-6. View

4.
Hermans C, de Moerloose P, Fischer K, Holstein K, Klamroth R, Lambert T . Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia. 2011; 17(3):383-92. DOI: 10.1111/j.1365-2516.2010.02449.x. View

5.
Souza J, Simoes H, Campbell C, Pontes F, Boullosa D, Prestes J . Haemophilia and exercise. Int J Sports Med. 2011; 33(2):83-8. DOI: 10.1055/s-0031-1286292. View